Home > Áreas Terapéuticas > ENFERMEDADES RARAS > de Andrés-Nogales F, Cruz E, Calleja MA, Delgado O, Gorgas Torner MQ, Espín J, Mestre-Ferrándiz J, Palau F, Ancochea A, Arce R, Domínguez-Hernández R, Casado MA and on behalf of the FinMHU-MCDA Group

de Andrés-Nogales F, Cruz E, Calleja MA, Delgado O, Gorgas Torner MQ, Espín J, Mestre-Ferrándiz J, Palau F, Ancochea A, Arce R, Domínguez-Hernández R, Casado MA and on behalf of the FinMHU-MCDA Group

de Andrés-Nogales F, Cruz E, Calleja MA, Delgado O, Gorgas Torner MQ, Espín J, Mestre-Ferrándiz J, Palau F, Ancochea A, Arce R, Domínguez-Hernández R, Casado MA and on behalf of the FinMHU-MCDA Group

 

A Multi-Stakeholder Multicriteria Decision Analysis for the Reimbursement of Orphan Drugs (FinMHU-MCDA study)
Orphanet J Rare Dis. 2021 Apr 26;16(1):186